V
Viola Klück
Researcher at Radboud University Nijmegen
Publications - 15
Citations - 488
Viola Klück is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Hyperuricemia & Gout. The author has an hindex of 8, co-authored 12 publications receiving 223 citations. Previous affiliations of Viola Klück include Radboud University Nijmegen Medical Centre & University of Colorado Denver.
Papers
More filters
Journal ArticleDOI
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial
Viola Klück,T.L.Th.A. Jansen,Matthijs Janssen,Antoaneta Comarniceanu,M. Efde,Isak W. Tengesdal,Kiki Schraa,Maartje C. P. Cleophas,Curtis L. Scribner,Damaris B. Skouras,Carlo Marchetti,Charles A. Dinarello,Charles A. Dinarello,Leo A. B. Joosten,Leo A. B. Joosten +14 more
TL;DR: Dapansutrile is a specific NLRP3 inflammasome inhibitor with a satisfactory safety profile and efficacy in the reduction of target joint pain in this study.
Journal ArticleDOI
Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia.
TL;DR: It is argued that hyperuricemia is a main culprit in the development of the long‐term systemic inflammation seen in gout and it is enforced that urate is a metabolite that can induce innate immune memory.
Journal ArticleDOI
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout
David Bursill,William J. Taylor,Robert Terkeltaub,Abhishek Abhishek,Alexander So,Ana Beatriz Vargas-Santos,Angelo L. Gaffo,Ann K. Rosenthal,Ann K. Rosenthal,Anne Kathrin Tausche,Anthony M. Reginato,Bernhard Manger,Carlo Alberto Scirè,Carlos Pineda,Caroline van Durme,Ching Tsai Lin,Congcong Yin,Daniel A. Albert,Edyta Biernat-Kaluza,Edward Roddy,Eliseo Pascual,Fabio Becce,Fernando Perez-Ruiz,Francisca Sivera,Frédéric Lioté,Georg Schett,George Nuki,Georgios Filippou,Geraldine M. McCarthy,Geraldo da Rocha Castelar Pinheiro,Hang-Korng Ea,Helena De Almeida Tupinambá,Hisashi Yamanaka,Hyon K. Choi,James Mackay,James R. O'Dell,Janitzia Vázquez Mellado,Jasvinder A. Singh,John FitzGerald,Lennart T H Jacobsson,Leo A. B. Joosten,Leslie R. Harrold,Lisa K. Stamp,Mariano Andrés,Marwin Gutierrez,Masanari Kuwabara,Mats Dehlin,Matthijs Janssen,Michael Doherty,Michael S. Hershfield,Michael H. Pillinger,N. Lawrence Edwards,Naomi Schlesinger,Nitin Kumar,Ole Slot,Sébastien Ottaviani,Pascal Richette,Paul MacMullan,Peter T. Chapman,Peter E. Lipsky,Philip Robinson,Puja P. Khanna,Rada N. Gancheva,Rebecca Grainger,Richard J. Johnson,Ritch Te Kampe,Robert T. Keenan,Sara K. Tedeschi,Seoyoung C. Kim,Sung Jae Choi,Theodore R. Fields,Thomas Bardin,Till Uhlig,T.L.Th.A. Jansen,Tony R. Merriman,Tristan Pascart,Tuhina Neogi,Viola Klück,Worawit Louthrenoo,Nicola Dalbeth +79 more
TL;DR: Consensus agreement has been established for the labels and definitions of eight gout disease states, including ‘gout’ itself, and the Gout, Hyperuricaemia and Crystal-Associated Disease Network recommends the use of these labels when describing disease states of gout in research and clinical practice.
Journal ArticleDOI
Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue.
Dov B. Ballak,Dov B. Ballak,Suzhao Li,Giulio Cavalli,Jonathan Lucien Stahl,Isak W. Tengesdal,Janna A. van Diepen,Viola Klück,Benjamin J Swartzwelter,Tania Azam,Cees J. Tack,Rinke Stienstra,Rinke Stienstra,Thomas Mandrup-Poulsen,Douglas R. Seals,Charles A. Dinarello,Charles A. Dinarello +16 more
TL;DR: It is shown that IL-37's anti-inflammatory effects can ameliorate established metabolic disturbances during obesity, and this results indicate that the HFD protected mice expressing human interleukin 37 are protected against metabolic syndrome.
Journal ArticleDOI
Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout
Viola Klück,Rosanne C. van Deuren,Giulio Cavalli,Amara Shaukat,Peer Arts,Maartje C. P. Cleophas,Tania O Crișan,Anne-Kathrin Tausche,Philip Riches,Nicola Dalbeth,Lisa K. Stamp,Jennie Harré Hindmarsh,T.L.Th.A. Jansen,Matthijs Janssen,Marloes Steehouwer,Stefan H. Lelieveld,Maartje van de Vorst,Christian Gilissen,Lorenzo Dagna,Frank L. van de Veerdonk,Elan Z. Eisenmesser,Soohyun Kim,Tony R. Merriman,Alexander Hoischen,Mihai G. Netea,Charles A. Dinarello,Leo A. B. Joosten +26 more
TL;DR: The carrier status of p.(N182S)(rs752113534) was associated with increased risk of developing gout in hyperuricaemic individuals of Polynesian ancestry and the therapeutic potential of recombinant IL-37 for the treatment of gouty arthritis was highlighted.